A photo of Daniel Lovell.

Associate Director, Division of Rheumatology

Professor, UC Department of Pediatrics



Board Certified

Make an Appointment

"I view my responsibility in treating each child as a sacred trust and know that I’m participating in the care for the most important person in the parents’ world."

My Biography & Research


Since I was 10 years old, I knew I wanted to be a doctor, and I am forever grateful that I stayed with my ambition. I came to pediatrics because I find it truly compelling to help children. I treat each child the same way I would want one of my own children to be treated if they had a rheumatic disease. I view my responsibility in treating each child as a sacred trust and know that I’m participating in the care for the most important person in the parents’ world.

I chose rheumatology after a patient in the hospital where I trained in pediatrics was admitted with juvenile idiopathic arthritis. There was no one at that hospital that specialized in pediatric rheumatology. As I learned then, and it is still true today, there are always at least 10 states in the U.S. without even one pediatric rheumatologist. The need was obvious.

In my practice, I specialize in the evaluation and care of children with rheumatic and related diseases, such as arthritis, lupus, dermatomyositis, scleroderma and various types of vasculitis.

The care of children with rheumatic diseases requires a team of healthcare providers including rheumatologists and other medical specialists, occupational and physical therapists, specialized nurses and social workers. In our Rheumatology Clinic, we have such a team, and every team member was hand-picked for their dedication and experience in caring for children with a rheumatic disease.

Our division is truly committed to providing the most sophisticated and effective therapy in the world for children with rheumatic diseases. This has been a core value of the Division of Rheumatology since it was founded.

I have received three awards that are most dear to me. I am the Joseph E. Levinson Endowed Chair in Pediatric Rheumatology, which is an award from the Cincinnati Children’s Hospital Research Foundation. Dr. Joseph Levinson founded this Division of Rheumatology and was my first boss in my first job as a pediatric rheumatologist. Over time, he became my mentor and friend. I am truly honored to hold a position named after him.

I received the 2019 James Cassidy Award from the American Academy of Pediatrics. Early in my career, I was given the Earl Brewer Research Award from the Arthritis Foundation. I was blessed enough to know and work with both Drs. Cassidy and Brewer, who were founding fathers of our specialty in North America.

My entire research career has been focused on identifying and evaluating more effective treatments for children with rheumatic diseases. I chair an international network of pediatric rheumatology centers called the Pediatric Rheumatology Collaborative Study Group (PRCSG). All the new therapies approved by the Food and Drug Administration for use in the treatment of children with rheumatic diseases in the last 30 years were approved based on studies performed by the PRCSG.

In my free time, my favorite thing to do is to ride horses in the Teton Wilderness. I’ve learned the hard way how to ride for six to eight hours per day. I also love being a grandfather and find it to be a wonderful, never-ending source of joy.

Clinical Interests

Diagnostic evaluation and ongoing care of children with all pediatric onset rheumatic diseases

Research Interests

Performance of clinical trials in children with rheumatic diseases; clinical trials methodology; mentoring of junior faculty

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Rheumatology, Lupus

Research Divisions


My Locations

My Education

MD: University of Kansas, Kansas City, KS, 1978.

MPH: University of Texas School of Public Health, Houston, TX, 1982.

Residency: Children's Mercy Hospital, Kansas City, KS.

Fellowship: Baylor College of Medicine, Houston, TX.

Certification: Pediatrics, 1984; Pediatric Rheumatology, 1992.

My Publications

Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. Lovell, DJ; Huang, B; Chen, C; Angeles-Han, ST; Simon, TA; Brunner, HI. RMD Open. 2021; 7.

Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Brunner, HI; Ruperto, N; Zuber, Z; Cuttica, R; Keltsev, V; Xavier, RM; Burgos-Vargas, R; Penades, IC; Silverman, ED; Espada, G; et al. Arthritis and Rheumatology. 2021; 73:530-541.

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Ruperto, N; Brunner, HI; Ramanan, AV; Horneff, G; Cuttica, R; Henrickson, M; Anton, J; Boteanu, AL; Penades, IC; Minden, K; et al. Rheumatology. 2021.

Open-Label Phase 3 Study of Intravenous Golimumab in Patients With Polyarticular Juvenile Idiopathic Arthritis. Ruperto, N; Brunner, HI; Pacheco-Tena, C; Louw, I; Vega-Cornejo, G; Spindler, AJ; Kingsbury, DJ; Schmeling, H; Borzutzky, A; Cuttica, R; et al. Rheumatology. 2021.

Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large pediatric rheumatology center in US. Yue, X; Huang, B; Hincapie, AL; Wigle, PR; Li, Y; Qiu, T; Lovell, DJ; Morgan, EM; Guo, JJ. Rheumatology. 2020.

Children with enthesitis-related arthritis could benefit from treatments targeted for adults with spondyloarthritis. Weiss, PF; Fuhlbrigge, RC; von Scheven, E; Lovell, DJ; Colbert, RA; Brunner, HI; PRCSG Advisory Council, the CARRA Executive Commit, . Arthritis Care and Research. 2020.

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. Pediatric Rheumatology. 2020; 18.

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Brunner, HI; Tzaribachev, N; Cornejo, GV; Joos, R; Gervais, E; Cimaz, R; Calvo Penades, I; Cuttica, R; Lutz, T; Quartier, P; et al. Pediatric Rheumatology. 2020; 18.

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Giancane, G; Swart, JF; Castagnola, E; Groll, AH; Horneff, G; Huppertz, H; Lovell, DJ; Wolfs, T; Herlin, T; Dolezalova, P; et al. Arthritis Research and Therapy. 2020; 22.

Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. Simon, TA; Harikrishnan, GP; Kawabata, H; Singhal, S; Brunner, HI; Lovell, DJ. Pediatric Rheumatology. 2020; 18.